During Wednesday’s Current trade, Shares of VMware, Inc. (NYSE:VMW), lost -0.66% to $88.58.
VMware, Inc. (VMW), a global leader in cloud infrastructure and business mobility, declared recently a comprehensive solution to support Windows 10. Customers upgrading to Windows 10 can take advantage of the administration, transition and app delivery tools offered by the VMware Operatespace™ Suite, which comprises AirWatch® Enterprise Mobility Administration™, VMware Horizon®, VMware Identity Manager™ and VMware Horizon® FLEX™.
Windows 10 is positioned as a milestone release for Microsoft and represents a fundamental shift in the way IT can manage all devices running the new software. As the vast majority (96 percent) of enterprises surveyed plan to use internal resources and existing staff to upgrade, according to a July 2015 TechValidate study commissioned by VMware, VMware supports the Windows 10 platform by providing tools internal IT departments need to assist manage devices, deliver all application types and activate the new features introduced in Windows 10. VMware solutions are purpose-built to support customers embracing business mobility and updating to Windows 10, while ongoing to support earlier Windows versions.
VMware, Inc. provides virtualization infrastructure solutions in the United States and internationally. The company’s virtualization infrastructure solutions comprise a suite of products designed to deliver a software-defined data center (SDDC), run on industry-standard desktop computers and servers, and support a range of operating system and application environments, in addition to networking and storage infrastructures. Its solutions enable organizations to aggregate multiple servers, storage infrastructure, and netoperates together into shared pools of capacity.
Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD), declined -2.71% to $15.87, during its current trading session.
Amicus Therapeutics (FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, recently declared financial results for the second quarter ended June 30, 2015. The Company also offered program updates and reiterated full-year 2015 net cash spend guidance of $100 million to $110 million.
Financial Highlights for Second Quarter Ended June 30, 2015
- Cash, cash equivalents, and marketable securities totaled $361.4 million at June 30, 2015, contrast to $169.1 million at December 31, 2014.
- Total operating expenses raised to $26.9 million contrast to $14.7 million for the second quarter 2014, primarily due to enhances in preclinical and clinical development costs on the Fabry monotherapy and Pompe ERT programs.
- Net loss was $27.1 million, or $0.27 per share, contrast to a net loss of $14.6 million, or $0.22 per share, for the second quarter 2014.
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its product candidate is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The company’s development programs comprise next-generation ERTs for lysosomal storage disorders (LSDs), such as Fabry disease, Pompe disease, and Mucopolysaccharidosis Type I.
Amarin Corporation plc (ADR) (NASDAQ:AMRN), during its Wednesday’s current trading session decreased -2.68% to $2.18.
Amarin Corporation plc (ADR) (AMRN) declared the presentation of findings from a new in vitro study at a peer-reviewed poster session at the American Diabetes Association Scientific Sessions in Boston, Massachusetts.
The poster, titled “Eicosapentaenoic Acid (EPA) Reduces Glucose-induced Small Dense Low-Density Lipoprotein Oxidation In Vitro in a Manner Distinct from Other Triglyceride-Lowering Agents and Vitamin E,” presents data that shows exposure to eicosapentaenoic acid (EPA), an omega-3 fatty acid, inhibited glucose-induced oxidation of small dense LDL. This study examined the effects of EPA and other triglyceride-lowering agents on human sdLDL oxidation following exposure in vitro to hyperglycemic conditions. Exposure to hyperglycemic conditions resulted in a 55% enhance in human sdLDL oxidation as contrast to non-glucose-treated controls as measured by a marker of oxidation (malondialdehyde (MDA)). EPA inhibited this glucose-induced sdLDL oxidation in a dose-dependent fashion and, at the highest concentration tested (10.0 µM), EPA inhibited sdLDL oxidation by 94% contrast to vehicle treated (ethanol) control.
Amarin Corporation plc, a biopharmaceutical company, focuses on developing and commercializing therapeutics for the treatment of cardiovascular diseases in the United States.
Finally, PDL BioPharma Inc (NASDAQ:PDLI), decreased -1.51%, to $5.87.
PDL BioPharma, Inc. (PDL) (PDLI) stated financial results for the second quarter and six months ended June 30, 2015.
Total revenues were $138.1 million for the three months ended June 30, 2015, contrast to $162.8 million for the same period of 2014, and $287.8 million for the six months ended June 30, 2015, contrast to $299.6 million for the six months ended June 30, 2014. During the three and six months ended June 30, 2015 and 2014, our Queen et al. royalty revenues compriseed of royalties and maintenance fees earned on sales of products under license agreements associated with our Queen et al. patents. During the three and six months ended June 30, 2015 and 2014, royalty rights - change in fair value comprised of revenues associated with the change in fair value of our royalty right assets, primarily Depomed, Inc., The Regents of the University of Michigan, and Viscogliosi Brothers, LLC. Revenues for the quarter ended June 30, 2015 comprised of $116.9 million in royalty and license payments from PDL’s licensees to the Queen et al. patents, $12.2 million in net royalty payments from attained royalty rights and a change in fair value of the royalty rights assets, which comprised of about $1.2 million in net cash royalty rights payments, and $9.0 million in interest revenue from notes receivable debt financings to late-stage healthcare companies. Revenues for the six months ended June 30, 2015 comprised of $244.7 million in royalty and license payments from PDL’s licensees to the Queen et al. patents, $23.6 million in net royalty payments from attained royalty rights and a change in fair value of the royalty rights assets, which comprised of about $2.1 million in net cash royalty rights payments, and $19.5 million in interest revenue from notes receivable debt financings to late-state healthcare companies.
PDL BioPharma, Inc. manages a portfolio of patents and royalty assets in the United States and Europe. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It offers Queen et al. patents that cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized antibodies.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
